ABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of Nsclc, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
ABVC Biopharma签署了治疗非小细胞肺癌的全球许可最终协议,预计总收入为1375万美元,特许权使用费高达1,250万美元
ABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of Nsclc, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
ABVC Biopharma签署了治疗非小细胞肺癌的全球许可最终协议,预计总收入为1375万美元,特许权使用费高达1,250万美元
使用浏览器的分享功能,分享给你的好友吧